Allegro Ophthalmics is establishing integrin peptide therapy as the next-generation pharmaceutical category for the treatment of neovascular retinal diseases. Our lead investigational drug, Luminate, has successfully met the endpoints for its first three Phase 2 studies and has demonstrated the ability to significantly reduce the current burden of intravitreal injections and treat non-responsive patients with diabetic macular edema and age-related macular degeneration.

By bringing to market new and improved treatment options for leading causes of blindness, we demonstrate our commitment to offering patients an improved quality of life sustained by self-sufficient, functional vision.